OncoHost, a global leader in precision oncology and proteomics-based biomarker development, today announced the presentation of two new research posters at the 2025 International Society for Liquid ...

New methods of testing tissue and plasma beyond next-generation sequencing (NGS) could be used to deliver the best ...

Researchers have discovered that targeting PD-L1 recycling in myeloid cells enhances T-cell activation and boosts the effects ...

The study will test the antibody-drug conjugate in combination with Keytruda in patients with HER2-overexpressing metastatic non-small cell lung cancer.

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.

The use of immunotherapy in patients with various types of cancer has led to dramatic increases in survival. Increased median ...

Regeneron Canada Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by public drug programs in Ontario, British Columbia, Saskatchewan, Nova Scotia, Newfoundland and ...

CNW/ - Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by Régie de l'assurance maladie du ...

Background Anti-C1q autoantibodies can disrupt normal complement function, contributing to the formation of pathogenic immune ...

European Commission approves Merck’s Keytruda as part of a treatment regimen for adults with resectable LA-HNSCC expressing PD-L1: Rahway, New Jersey Thursday, October 30, 2025, ...